SPTLC1

Serine palmitoyltransferase 1 · O15269 · SPTLC1 on Sugi Atlas →

1,693 patent compounds predicted against SPTLC1, 1,345 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL4697866 SCHEMBL4697866 0.89 2/20
SCHEMBL4697696 SCHEMBL4697696 0.86 2/20
SCHEMBL4699140 SCHEMBL4699140 0.80 2/20
SCHEMBL4698636 SCHEMBL4698636 0.76 2/20
SCHEMBL14217995 SCHEMBL14217995 0.76 2/20
SCHEMBL14190669 SCHEMBL14190669 0.75 2/20
SCHEMBL4699183 SCHEMBL4699183 0.74 2/20
SCHEMBL4696222 SCHEMBL4696222 0.72 2/20
SCHEMBL14217994 SCHEMBL14217994 0.72 2/20
SCHEMBL4701699 SCHEMBL4701699 0.70 2/20
SCHEMBL4920392 SCHEMBL4920392 0.66 2/20
SCHEMBL6748227 SCHEMBL6748227 0.64 2/20
SCHEMBL4696804 SCHEMBL4696804 0.62 2/20
SCHEMBL4701647 SCHEMBL4701647 0.62 2/20
SCHEMBL14217993 SCHEMBL14217993 0.61 2/20
SCHEMBL4919390 SCHEMBL4919390 0.61 2/20
SCHEMBL14070207 SCHEMBL14070207 0.59 2/20
SCHEMBL14070215 SCHEMBL14070215 0.59 2/20
SCHEMBL14070277 SCHEMBL14070277 0.58 2/20
SCHEMBL14069857 SCHEMBL14069857 0.56 2/20

Clinical trials — most relevant to SPTLC1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis PHASE4COMPLETED
Hereditary Sensory Neuropathy Serine Trial PHASE2UNKNOWN
Anti-inflammatory Pulmonal Therapy of Cystic Fibrosis (CF) Patients With Amitriptyline and Placebo PHASE2UNKNOWN
Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo PHASE2COMPLETED
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides PHASE1COMPLETED
Sphingo-lipotoxicity and Trans-differentiation of Adipose Tissue in Obesity (SFINGOTRANS) nanCOMPLETED
Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children nanWITHDRAWN
Lipidomic and Multi-Omics Profiling of Fatty Liver Disease in People With and Without HIV nanNOT_YET_RECRUITING
Ceramide Level as Apredictor of Outcomes in Patients of Anterior Myocardial Infarction Undergoing Primary Coronary Intervention nanUNKNOWN
Structural Network on Prostate Cancer in the French Greater West Region nanCOMPLETED
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia nanUNKNOWN
Vulvodynia: Identification of Potential Relevant Biomarkers nanCOMPLETED
Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans nanCOMPLETED
Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma nanRECRUITING
Plasma Dihydroceramides Are Associated With Hepatic Steatosis in Type 1 and Type 2 Diabetes nanCOMPLETED
Genetic and Environmental Determinants of Triglycerides (GOLDN) nanCOMPLETED
Evaluating the Association Between Sphingolipid Metabolites and Post-hepatectomy Liver Failure nanCOMPLETED
Stearoyl-CoA Desaturase and Energy Metabolism in Humans nanCOMPLETED
Genomic Dissection of a QTL Affecting the Lipid Profile nanWITHDRAWN
Studying Lipids as Potential Biomarkers in Patients With Fabry Disease nanCOMPLETED
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
Study of the Prevalence of Acid Sphingomyelinase Deficiency/Niemann Pick AB and B Disease in Patients With Diffuse Interstitial Lung Disease nanNOT_YET_RECRUITING
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity. nanCOMPLETED
The ASTERS Study: Assessing the Role of Sphingolipids in AcuTE Respiratory Distress Syndrome (ARDS) nanCOMPLETED
Genes Involved in Lipid Disorders nanCOMPLETED
Biomarker for Farber Disease (BioFarber) nanWITHDRAWN
Role of Dairy Products in Weight Maintenance nanCOMPLETED
Targeting zDHHC Enzymes to Counteract Alzheimer's Disease nanNOT_YET_RECRUITING
Identification of Women With Severe Insulin Resistant Syndromes of Genetic Origin Among Patients With Classic Polycystic Ovary Syndrome (PCOS) nanNOT_YET_RECRUITING
Epidemiology of Atherosclerosis nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SPTLC1 binder may also engage these)

ProteinNameSimilarity
O54695 1.000 O54695 →
D4A2H2 1.000 D4A2H2 →
Q3MHG1 1.000 Q3MHG1 →
Q60HD1 1.000 Q60HD1 →
Q5R9T5 1.000 Q5R9T5 →
O35704 0.999 O35704 →
Q10P01 0.987 Q10P01 →
Q6K8E7 0.986 Q6K8E7 →
Q94IB8 0.986 Q94IB8 →
Q7G4P2 0.981 Q7G4P2 →
P91079 0.978 P91079 →
Q6NYL5 0.974 Q6NYL5 →
Q8BGT5 0.974 Q8BGT5 →
Q6GM82 0.972 Q6GM82 →
Q7XQ85 0.972 Q7XQ85 →
P17735 0.971 P17735 →
P70712 0.971 P70712 →
Q58CZ9 0.971 Q58CZ9 →
Q9S7E9 0.969 Q9S7E9 →
Q28DB5 0.968 Q28DB5 →
Q8TD30 0.967 Q8TD30 →
Q8QZR1 0.967 Q8QZR1 →
Q7XHL3 0.967 Q7XHL3 →
P04694 0.967 P04694 →
Q07262 0.966 Q07262 →
P14173 0.965 P14173 →
Q28EN2 0.965 Q28EN2 →
Q9CXF0 0.964 Q9CXF0 →
Q06086 0.964 Q06086 →
Q9C969 0.964 Q9C969 →